NIH-funded research R01 grant

Reminders and small rewards to help people with HIV take their HIV pills regularly

Official title: INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)

Funded at Rand Corporation · NIH-11171473 · Data updated 2026-11-12

This project uses daily reminders and small rewards to help people living with HIV take their antiretroviral pills regularly.

More Medication Adherence research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionRand Corporation
NIH-funded
Lab location1 site (Santa Monica, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2029
Funding year2025
Award (this year)$582,359
NIH project number5R01MH135751-02
Project IDNIH-11171473 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are adults living with HIV who are prescribed antiretroviral therapy and want help forming a reliable pill-taking routine or who sometimes miss doses.

Less likely to help

People who are already consistently adherent to every dose or who cannot receive daily messages or accept small incentives (due to phone access, privacy concerns, or preference) are less likely to benefit.

What this research studies

If you join, you'll be asked to pick an existing daily habit (an "anchor")—like breakfast or brushing your teeth—to pair with taking your HIV pill so it becomes automatic. Some participants will get daily reminder messages for three months to help stick to their anchoring plan, while another group will receive the same messages plus small monthly prizes when they take pills around their chosen routine. The team will monitor medication-taking using self-reports, electronic measures, and clinic lab results such as viral load. This larger project builds on a successful pilot and aims to create lasting pill-taking routines for more people.

Why it matters

Potential benefit: If successful, the approach could help more people with HIV keep taking their ART on schedule and raise rates of viral suppression.

How similar studies have gone: A prior pilot (R34) from this team showed promising results using reminders and small incentives to form pill-taking routines, though larger confirmatory testing is still needed.

Where this research is happening

  • Rand Corporation
    Santa Monica, United States
    Active

Researchers

  • Principal investigator: Linnemayr, Sebastian — Rand Corporation
  • Study coordinator: Linnemayr, Sebastian

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.